PCM
CLVS

Prelude Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Prelude Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-626
Closed -$5.02K – 2195
2019
Q4 		$7K Sell
626
-76
-11% -$553 ﹤0.01% 1746
2019
Q3 		$3K Sell
702
-6
-0.8% -$49 ﹤0.01% 1611
2019
Q2 		$11K Sell
708
-2
-0.3% -$36 ﹤0.01% 1380
2019
Q1 		$18K Buy
710
+695
+4,633% +$17.4K ﹤0.01% 1336
2018
Q4 		$0 Sell
15
-19,353
-100% -$395K ﹤0.01% 2274
2018
Q3 		$569K Buy
19,368
+11,668
+152% +$452K 0.03% 491
2018
Q2 		$350K Buy
7,700
+2,548
+49% +$124K 0.02% 628
2018
Q1 		$272K Buy
5,152
+4,677
+985% +$273K 0.02% 608
2017
Q4 		$32K Sell
475
-7,492
-94% -$524K ﹤0.01% 1034
2017
Q3 		$656K Sell
7,967
-9,769
-55% -$774K 0.06% 318
2017
Q2 		$1.66M Buy
17,736
+16,205
+1,058% +$992K 0.16% 137
2017
Q1 		$97K Sell
1,531
-4,473
-75% -$272K 0.01% 793
2016
Q4 		$267K Buy
+6,004
New +$211K 0.03% 475
2015
Q4 		– Sell
-3,806
Closed -$350K – 1754
2015
Q3 		$350K Sell
3,806
-5,044
-57% -$437K 0.05% 378
2015
Q2 		$778K Hold
8,850
– – 0.11% 216
2015
Q1 		$657K Buy
+8,850
New +$625K 0.09% 262

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Prelude Capital Management's CLVS Position: Q1 2020 in Review

Prelude Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 626 shares — an estimated $5.02K sold.

Prelude Capital Management first reported a position in CLVS in Q1 2015 and held it in 16 quarters. The position peaked at $1.66M in Q2 2017. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

  • Prelude Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 626 Clovis Oncology, Inc. shares in Q1 2020, an estimated $5.02K.
  • Prelude Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 16 quarters.
  • Prelude Capital Management's Clovis Oncology, Inc. position peaked at $1.66M in Q2 2017.
  • 154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.